Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1 Pipeline Review, H1 2018
Summary
According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 4 Pipeline Review, H1 2018'; Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1 pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1 Receptor tyrosineprotein kinase erbB4 is an enzyme that in humans is encoded by the ERBB4 gene. Receptor tyrosineprotein kinase erbB4 is a receptor tyrosine kinase that is a member of the epidermal growth factor receptor subfamily. it plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. It is required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation, normal development of the embryonic central nervous system, especially for normal neural crest cell migration, normal axon guidance, mammary gland differentiation, induction of milk proteins and lactation. It acts as cellsurface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors.
The report 'Receptor Tyrosine Protein Kinase ERBB 4 Pipeline Review, H1 2018' outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in PreRegistration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1, 4, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Gastrointestinal which include indications NonSmall Cell Lung Cancer, Gastric Cancer, Metastatic Breast Cancer, Solid Tumor, Esophageal Cancer, Breast Cancer, Colorectal Cancer, Glioblastoma Multiforme GBM, Bile Duct Cancer Cholangiocarcinoma, Lung Adenocarcinoma, Metastatic Brain Tumor, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Cervical Cancer, Chordoma, Chronic Heart Failure, Crohn's Disease Regional Enteritis, Endometrial Cancer, Ependymoma, Gallbladder Cancer, Gastroesophageal GE Junction Carcinomas, Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, HighGrade Glioma, Leptomeningeal Disease Neoplastic Meningitis, Leptomeningeal Carcinomatosis, LowGrade Astrocytoma, LowGrade Glioma, Lung Cancer, Medulloblastoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Hepatocellular Carcinoma HCC, Metastatic Transitional Urothelial Tract Cancer, Necrotizing Enterocolitis, Neuroblastoma, Oligodendroglioma, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Pituitary Tumor, Primitive Neuroectodermal Tumor PNET, Recurrent Glioblastoma Multiforme GBM, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Malignant Glioma, Rhabdomyosarcoma, Skin Cancer, Systolic Heart Failure, Ulcerative Colitis, Urinary Tract Cancer and Uterine Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1
The report reviews Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1 targeted therapeutics and enlists all their major and minor projects
The report assesses Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope